Some lots of irbesartan being recalled due to contamination with suspected carcinogen
THURSDAY, Nov. 1, 2018 (HealthDay News) — Another hypertension drug is being recalled due to contamination that could pose a cancer risk, the U.S. Food and Drug Administration says.
Certain lots of irbesartan are being recalled by SciGen because they contain an industrial chemical that is a suspected carcinogen, CNN reported. The recalled drugs have “Westminster Pharmaceuticals” and “GSMS Inc.” on the label.
Another heart drug, valsartan, was recalled recently due to contamination with possible cancer-causing chemicals, CNN reported.
Not all medicines that contain valsartan or irbesartan are being recalled. The new recall covers only about 1 percent of irbesartan drug products available in the United States, according to the FDA.
Mortality in Injured Children Linked to Higher SBP Thresholds Than Those That Define Hypotension
Eating More Whole Grains Daily Linked to Cardiometabolic Benefits
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors
Midlife Onset of Increasing Pulse Pressure Not Linked to Menopause
Longer Reproductive Lifespan Tied to Lower Bronchiectasis Risk in Postmenopausal Women
Intensive BP Lowering Reduces Recurrent Stroke After Intracerebral Hemorrhage
Estrogen Hormone Treatment May Be Beneficial for Brain Fog Symptoms in Menopausal Women
Onset of Mortality, Morbidity Delayed for Offspring of Centenarians